Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -

Karolinska University Hospital23 enrolled

Overview

A study on patients who are hospitalized and tested positive for COVID-19 or have a typical CT image of COVID-19 infection, to establish if omega-3 Polyunsaturated Fatty Acid (PUFA) supplementation by intravenous route is a possible treatment option in COVID-19 with minimal risks to the patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

COVID-19

Interventions

Omegaven®DRUG

A highly refined fish oil in an emulsion for infusion with purified egg phosphatides and glycerol.

Sodium chlorideDRUG

intravenously administered 2 mL/kg/day

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Provision of signed informed consent prior to any study specific procedures. 2. Female and male patients ≥18 years of age. 3. COVID-19 positive or typical CT image of COVID-19 infection. 4. Clinical status requiring hospitalization. Exclusion Criteria: 1. According to Omegaven® contraindications (serious bleeding disorders, acute life-threatening condition, including acute shock, acute myocardial infarction, acute stroke, acute emboli, and coma). 2. Known hypersensitivity to Omegaven® or any of the ingredients. 3. Participation in any clinical research study evaluating an investigational medicinal product (IMP) within 3 months prior to screening. 4. Pregnancy and breastfeeding.

Locations (2)

Karolinska Universitetssjuhuset

Stockholm, Sweden

Södersjukhuset

Stockholm, Sweden